Literature DB >> 24702117

Post-transcriptional regulation of interferons and their signaling pathways.

Ram Savan1.   

Abstract

Interferons (IFNs) are low molecular weight cell-derived proteins that include the type I, II, and III IFN families. IFNs are critical for an optimal immune response during microbial infections while dysregulated expression can lead to autoimmune diseases. Given its role in disease, it is important to understand cellular mechanisms of IFN regulation. 3' untranslated regions (3' UTRs) have emerged as potent regulators of mRNA and protein dosage and are controlled through multiple regulatory elements including adenylate uridylate (AU)-rich elements (AREs) and microRNA (miRNA) recognition elements. These AREs are targeted by RNA-binding proteins (ARE-BPs) for degradation and/or stabilization through an ARE-mediated decay process. miRNA are endogenous, single-stranded RNA molecules ~22 nucleotides in length that regulate mRNA translation through the miRNA-induced silencing complex. IFN transcripts, like other labile mRNAs, harbor AREs in their 3' UTRs that dictate the turnover of mRNA. This review is a survey of the literature related to IFN regulation by miRNA, ARE-BPs, and how these complexes interact dynamically on the 3' UTR. Additionally, downstream effects of these post-transcriptional regulators on the immune response will be discussed. Review topics include past studies, current understanding, and future challenges in the study of post-transcriptional regulation affecting IFN responses.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24702117      PMCID: PMC4015472          DOI: 10.1089/jir.2013.0117

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  93 in total

1.  IL-28, IL-29 and their class II cytokine receptor IL-28R.

Authors:  Paul Sheppard; Wayne Kindsvogel; Wenfeng Xu; Katherine Henderson; Stacy Schlutsmeyer; Theodore E Whitmore; Rolf Kuestner; Ursula Garrigues; Carl Birks; Jenny Roraback; Craig Ostrander; Dennis Dong; Jinu Shin; Scott Presnell; Brian Fox; Betty Haldeman; Emily Cooper; David Taft; Teresa Gilbert; Francis J Grant; Monica Tackett; William Krivan; Gary McKnight; Chris Clegg; Don Foster; Kevin M Klucher
Journal:  Nat Immunol       Date:  2002-12-02       Impact factor: 25.606

2.  Postinduction repression of the beta-interferon gene is mediated through two positive regulatory domains.

Authors:  L A Whittemore; T Maniatis
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

Review 3.  The roles of IFN gamma in protection against tumor development and cancer immunoediting.

Authors:  Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Cytokine Growth Factor Rev       Date:  2002-04       Impact factor: 7.638

Review 4.  Interferons, immunity and cancer immunoediting.

Authors:  Gavin P Dunn; Catherine M Koebel; Robert D Schreiber
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

Review 5.  Action of interferon and its inducers aginst nonviral infectious agents.

Authors:  J Vilcek; R I Jahiel
Journal:  Arch Intern Med       Date:  1970-07

6.  Retinoic acid-inducible gene I-inducible miR-23b inhibits infections by minor group rhinoviruses through down-regulation of the very low density lipoprotein receptor.

Authors:  Ryota Ouda; Koji Onomoto; Kiyohiro Takahasi; Michael R Edwards; Hiroki Kato; Mitsutoshi Yoneyama; Takashi Fujita
Journal:  J Biol Chem       Date:  2011-06-03       Impact factor: 5.157

7.  miR-155 and its star-form partner miR-155* cooperatively regulate type I interferon production by human plasmacytoid dendritic cells.

Authors:  Haibo Zhou; Xinfang Huang; Huijuan Cui; Xiaobing Luo; Yuanjia Tang; Shunle Chen; Li Wu; Nan Shen
Journal:  Blood       Date:  2010-09-17       Impact factor: 22.113

8.  Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-130A.

Authors:  Joydip Bhanja Chowdhury; Shubham Shrivastava; Robert Steele; Adrian M Di Bisceglie; Ranjit Ray; Ratna B Ray
Journal:  J Virol       Date:  2012-07-11       Impact factor: 5.103

9.  Interferon modulation of cellular microRNAs as an antiviral mechanism.

Authors:  Irene M Pedersen; Guofeng Cheng; Stefan Wieland; Stefano Volinia; Carlo M Croce; Francis V Chisari; Michael David
Journal:  Nature       Date:  2007-10-18       Impact factor: 49.962

10.  MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins.

Authors:  Yuanjia Tang; Xiaobing Luo; Huijuan Cui; Xuming Ni; Min Yuan; Yanzhi Guo; Xinfang Huang; Haibo Zhou; Niek de Vries; Paul Peter Tak; Shunle Chen; Nan Shen
Journal:  Arthritis Rheum       Date:  2009-04
View more
  22 in total

Review 1.  Epithelial-to-Mesenchymal Transition Signaling Pathways Responsible for Breast Cancer Metastasis.

Authors:  Busra Buyuk; Sha Jin; Kaiming Ye
Journal:  Cell Mol Bioeng       Date:  2021-09-02       Impact factor: 3.337

Review 2.  Translating the Untranslated Region.

Authors:  Johannes Schwerk; Ram Savan
Journal:  J Immunol       Date:  2015-10-01       Impact factor: 5.422

3.  RNase L Reprograms Translation by Widespread mRNA Turnover Escaped by Antiviral mRNAs.

Authors:  James M Burke; Stephanie L Moon; Tyler Matheny; Roy Parker
Journal:  Mol Cell       Date:  2019-09-04       Impact factor: 17.970

4.  RNA-binding protein isoforms ZAP-S and ZAP-L have distinct antiviral and immune resolution functions.

Authors:  Johannes Schwerk; Frank W Soveg; Andrew P Ryan; Kerri R Thomas; Lauren D Hatfield; Snehal Ozarkar; Adriana Forero; Alison M Kell; Justin A Roby; Lomon So; Jennifer L Hyde; Michael Gale; Matthew D Daugherty; Ram Savan
Journal:  Nat Immunol       Date:  2019-11-18       Impact factor: 25.606

5.  TCR-CXCR4 signaling stabilizes cytokine mRNA transcripts via a PREX1-Rac1 pathway: implications for CTCL.

Authors:  Kimberly N Kremer; Brittney A Dinkel; Rosalie M Sterner; Douglas G Osborne; Dragan Jevremovic; Karen E Hedin
Journal:  Blood       Date:  2017-07-10       Impact factor: 22.113

Review 6.  Non-Coding RNAs in Tuberculosis Epidemiology: Platforms and Approaches for Investigating the Genome's Dark Matter.

Authors:  Ahmad Almatroudi
Journal:  Int J Mol Sci       Date:  2022-04-17       Impact factor: 6.208

7.  ELAVL1 primarily couples mRNA stability with the 3' UTRs of interferon-stimulated genes.

Authors:  Katherine Rothamel; Sarah Arcos; Byungil Kim; Clara Reasoner; Samantha Lisy; Neelanjan Mukherjee; Manuel Ascano
Journal:  Cell Rep       Date:  2021-05-25       Impact factor: 9.423

8.  Hepatic Interferon-λ3 (IFNL3) Gene Expression Reveals Not to Be Attenuated in Non-Favorable IFNL3 rs4803217 or IFNL4 rs368234815 Minor Allele Carriers in Chronic Hepatitis C.

Authors:  Ahmad Amanzada; Lars Reinhardt; Dorothea Fey; Elisabeth M Zeisberg; Sabine Mihm
Journal:  PLoS One       Date:  2015-11-25       Impact factor: 3.240

9.  Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis.

Authors:  E G Meissner; A Kohli; K Virtaneva; D Sturdevant; C Martens; S F Porcella; J G McHutchison; H Masur; S Kottilil
Journal:  J Viral Hepat       Date:  2016-02-03       Impact factor: 3.728

Review 10.  Cause and consequences of the activated type I interferon system in SLE.

Authors:  Maija-Leena Eloranta; Lars Rönnblom
Journal:  J Mol Med (Berl)       Date:  2016-04-20       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.